



**NervGen Pharma Corp.
Expanded Access Policy for NVG-291**

NervGen Pharma Corp. ("NervGen") is committed to developing safe and effective therapies for patients with serious or life-threatening conditions. Consistent with this mission, we are focused on enrolling and conducting the clinical trials necessary to gain regulatory approvals to make NVG-291 available to patients as quickly as possible. We believe this approach will best serve the broadest number of patients who could be helped by the therapies we are developing. At the same time, we understand that there are people with spinal cord injuries who participated in our clinical trials and may not have alternative therapeutic options. In these circumstances, provided that NVG-291 remains in active clinical development and an adequate supply of NVG-291 is available, NervGen will consider providing a requesting physician with pre-approval access to NVG-291 for the treatment of an individual patient outside of our ongoing clinical trial, when certain eligibility criteria are met.

These eligibility criteria, though not exhaustive, include the following:

- The individual participated in the ongoing NervGen Phase 1b/2a clinical trial (NVG-291-201), completed the study, is confirmed by NervGen to have received NVG-291 as their treatment, derived significant clinical benefit (as determined by their treating physician), and has no other available treatment options;
- The requesting physician is fully licensed and otherwise qualified to safely administer the drug, comply with local regulations for expanded access, and monitor and report adverse events, as required by the Institutional Review Board, the company, and regulatory bodies; and
- A benefit-risk analysis, based on the available clinical data as well as the requesting physician's assessment of the individual patient's condition and history, supports making NVG-291 available.

Discontinuation of Expanded Access Protocol: NervGen may consider discontinuing this Expanded Access protocol for various reasons, including but not limited to:

- New information becomes available about the efficacy or safety of NVG-291 that could substantially change its benefit/risk profile.
- Commercial availability of NVG-291.
- A NervGen decision not to continue the development of NVG-291 in clinical trials for chronic spinal cord injury.
- Limited product supply or other manufacturing issues.

We continually evaluate the benefit-risk profile of NVG-291 based on evolving clinical data. The fact that NVG-291 is made available for the treatment of a particular patient does not mean it will be made available in response to other requests on behalf of other patients whose

circumstances and medical histories may be different. Requests will be considered on a case-by-case basis. NervGen is committed to evaluating all requests in a fair and equitable manner. All requests must be submitted by the patient's treating physician; NervGen may require more detailed information to fully evaluate a request. Each request will be given careful consideration by NervGen.

Physicians seeking pre-approval access for patients should submit their requests to EAP@nervgen.com. The email should contain information sufficient for NervGen to evaluate the request consistent with this policy. NervGen will acknowledge receipt of requests within five (5) business days. This policy may be updated at any time and is not intended to create or imply any contract.